1. Scrip
  2. >>Focus On Asia
  3. >>South Korea

First Approval Bodes Well For Hanmi's Olmutinib

 
• By Jung Won Shin

Hanmi’s novel lung cancer drug olmutinib is set to debut on the South Korean market later this year following its first approval globally after a fast-track review. The therapy will gain a domestic head start over AstraZeneca’s Tagrisso and international licensing deals have already been reached with Boehringer Ingelheim and ZAI Lab.

X-ray lung cancer
Lung cancer X-ray • Source: Shutterstock

Hanmi Pharmaceutical Co. Ltd.’s novel third-generation epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI), olmutinib, has received an approval for lung cancer from South Korea’s Ministry of Food and Drug Safety (MFDS), paving the way for the drug to debut in this market ahead of its main competitor Tagrisso.

Hanmi expects to roll out the oral drug as Olita later this year, when it will become the first TKI...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Bitcoin Player Parataxis To Acquire Bridge Biotherapeutics After IPF Failure

 
• By Jung Won Shin

After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By Jung Won Shin

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges

MetaVia Sees Obesity Opportunities Despite Challenging US Market

 
• By Jung Won Shin

Despite new challenges related to obesity drug insurance coverage in the US, MetaVia's CEO is confident in the company's novel contender, which unlike rival GLP-1 therapies doesn’t require dose titration.

More from Focus On Asia

Torrent Acquires JB Chem In 2025’s Biggest Deal For Indian Pharma

 
• By Vibha Ravi

Torrent Pharma’s JB Chemicals acquisition follows the Curatio deal and Boehringer brands buyout. The second-biggest deal ever and the largest in 2025 among domestic pharma companies helps Torrent fill white spaces in areas like nephrology and gives an entry into the CDMO segment

Snapshot Of India’s Pharma Manufacturing Network Amid ‘Trumponomics’

 
• By Anju Ghangurde

Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut